Last reviewed · How we verify
Budiglimab
Budiglimab is a Small molecule drug developed by AbbVie. It is currently in discontinued development. Also known as: ABBV-181.
Budiglimab is an experimental treatment being studied in combination with modified FOLFIRINOX for pancreatic cancer. It is administered intravenously as part of a clinical trial (NCT04807972) to evaluate its safety and efficacy in this patient population.
At a glance
| Generic name | Budiglimab |
|---|---|
| Also known as | ABBV-181 |
| Sponsor | AbbVie |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budiglimab CI brief — competitive landscape report
- Budiglimab updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about Budiglimab
What is Budiglimab?
Who makes Budiglimab?
Is Budiglimab also known as anything else?
What development phase is Budiglimab in?
Related
- Manufacturer: AbbVie — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: ABBV-181
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing